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Background: Hypotony maculopathy (HM) changes may persist, and visual acuity remains 
poor, despite normalization of intraocular pressure (IOP). The aim of this study was to evaluate 
the visual and anatomical results of pars plana vitrectomy (PPV), internal limiting membrane 
(ILM) peeling, and 20% SF6 gas tamponade in five myopic patients with HM.
Methods: This retrospective interventional study was conducted at the Barraquer Center of 
Ophthalmology, a tertiary care center in Barcelona, Spain, and included five eyes from five 
consecutive patients (aged 55.4±13.1 years) with HM caused by different conditions. All the 
patients were treated with 23-gauge PPV, ILM peeling, and 20% SF6 gas tamponade. Preopera-
tive and postoperative evaluation was performed using anterior and posterior biomicroscopy 
and best corrected visual acuity (BCVA) by logMAR charts.
Results: Before surgery, median spherical equivalent was -13.1 (range -7, -19) diopters 
of myopia. Preoperatively, four cases presented IOP 6.5 mmHg for 3 (range 2–8) weeks. 
In three of these four cases, IOP 6.5 mmHg was achieved over 16 (range 16–28) weeks, 
without resolution of HM; increased IOP was not achieved in the remaining case treated 
2 weeks after diagnosis of HM. One case presented IOP 6.5 mmHg with HM for 28 weeks 
before surgery. Preoperative BCVA was 0.7 (range 0.26–2.3) logMAR, and 0.6 (range 0.3–0.7) 
logMAR and 0.5 (range 0.2–1) logMAR, respectively, at 4 and 12 months after surgery. There 
was no statistically significant difference between preoperative and postoperative BCVA. Hyper-
pigmentation lines in the macular area were observed in three cases with hypotony. These lines 
progressed after surgery despite resolution of the retinal folds in the three cases, and BCVA 
decreased in parallel in two of these cases.
Conclusion: PPV with ILM peeling followed by gas tamponade is a good alternative for the 
treatment of HM in myopic patients. However, persistent choroidal folds may compromise 
BCVA. We therefore recommend initiating treatment as early as possible.
Keywords: hypotony maculopathy, retinal pigment epithelial hyperpigmentation, macular 
folds, retinal pigment epithelium, vitrectomy
Introduction
Ocular hypotony is defined as a reduction in intraocular pressure (IOP).1 Pederson2 
differentiated “statistical” from “clinical” hypotony; the former refers to IOP 6.5 
mmHg, which is more than 3 standard deviations below the mean, whereas clinical 
hypotony is IOP that causes decreased visual acuity. Sustained low IOP can trigger 
structural and functional changes in the eyeball, including hypotony maculopathy 
(HM). This was first described in 1954 by Dellaporta,3 who reported four cases that he 
classified as “papilloedema ex vacuo”. These patients had hypotony, papilledema, vas-
cular tortuosity, and chorioretinal folds. The term “macular hypotony” was introduced 
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in 1972 by Gass,4 who described ten cases with similar fun-
duscopic alterations being responsible for visual loss.
HM is usually preceded by intraocular surgery, most 
commonly anti-glaucoma filtration, or penetrating trauma, 
leading to abnormally low IOP. Its incidence is reported 
as 1.3%–18%.5,6 In physiopathological terms, reduced IOP 
causes scleral shrinkage leading to redundancy of choroidal 
and retinal tissue with radial macular fold formation, optic 
disc edema, venous tortuosity, and a consequent decrease in 
visual acuity.4 Fluorescence angiography reveals alternating 
bands of hypofluorescence and hyperfluorescence consistent 
with the folds. Ocular coherence tomography (OCT) can 
detect subtle changes showing an irregular contour of the 
retina and choroid.7
First-line treatment for HM involves identifying the 
causes and implementing measures to increase IOP to reverse 
the scleral shrinkage. Sometimes, despite normalization of 
IOP, changes in the posterior pole may persist and visual 
acuity remains poor.8–10 Our approach in the present study 
was based on the hypothesis that pars plana vitrectomy 
(PPV) with internal limiting membrane (ILM) peeling and 
gas tamponade can improve visual acuity and fundus findings 
in patients with unresolved HM.
Patients and methods
We performed a retrospective interventional study of five 
eyes from five consecutive patients (four males, one female) 
aged 55.4±13.1 (range 32–62) years and undergoing vitreo-
retinal surgical treatment of HM. The study was carried out 
at the Barraquer Ophthalmology Center, Barcelona, Spain, 
between January 2008 and February 2011. The primary 
indication for PPV was unresolved HM, despite measures 
to normalize IOP (successful in some cases and unsuccess-
ful in others).
Preoperative evaluation (one week before surgery) 
included medical history, best corrected visual acuity 
(BCVA) by logMAR chart scale, refraction, metamorphop-
sia test, biomicroscopy of anterior and posterior segments, 
photographs of the posterior pole with a non-mydriatic 
retinal camera (CR6-47 NM, Canon Inc, Tokyo, Japan), 
IOP, etiology of hypotony, stage of glaucoma (based on the 
new International Classification of Diseases, 9th Revision 
[ICD-9] staging definitions) and preoperative and postop-
erative OCT (Spectral domain Cirrus HD-OCT and/or time 
domain Stratus was used).
Surgery was performed by the same surgeon in all 
cases. Anesthesia was peribulbar. The technique used was 
23-gauge complete PPV of the anterior, middle, and posterior 
segments with ILM peeling of more than 5,000 µm in 
diameter, staining with Brilliant Blue 0.25 mg/mL, followed 
by gas tamponade using 20% SF6. Leaking ports and ports 
with inappropriate tunnel sclerotomy incisions were sutured 
with 7/0 Vicryl. No positioning or avoidance of the supine 
position was indicated.
Postoperatively, one drop of tobramycin 3 mg/mL plus 
dexamethasone 1 mg/mL (Tobradex® Alcon, El Masnou, 
Barcelona, Spain) was administered four times a day dur-
ing the first week, then tapered to one drop per week for 
one month.
Postoperative evaluation included BCVA, a metamor-
phopsia test, IOP, biomicroscopy of anterior and posterior 
segments, glaucoma staging (based on the new ICD-9 
definitions), photographs of the posterior pole with a non-
mydriatic retinal camera (CR6-47NM, Canon) and OCT at 
4 and 12 months. Biomicroscopy of the anterior and posterior 
segment and IOP were also checked on the day of surgery 
and one week later.
Statistical analysis of BCVA scores was performed using 
Statistical Package for the Social Sciences software (SPSS 
Inc, Chicago, IL, USA) with the Wilcoxon test for repeated 
measures and 95% confidence intervals. Descriptive statistics 
are shown for each patient and means with interquartile range 
in Table 1, together with patient characteristics.
Results
Before surgery, all patients were myopic with a median 
spherical equivalent of -13.1 (range -7, -19). Preopera-
tively, four cases presented IOP 6.5 mmHg for a median 
of 3 (range 2–8) weeks. In three of these four cases, 
IOP 6.5 mmHg was achieved over 16 (range 16–28) weeks 
without HM resolution; increased IOP was not achieved 
in the remaining case, who was treated 2 weeks after HM. 
One case presented IOP 6.5 mmHg with HM for 7 months 
before surgery. The causes of hypotony were hyperfunction-
ality secondary to previous filtering surgery (three cases), 
hyperfunctional filtering bleb secondary to trauma (one case), 
and cyclodialysis (one case).
Measures to increase IOP (Table 1) were successful in 
three cases with statistical hypotony, but anatomofunctional 
changes were not resolved and they showed clinical hypotony 
(cases 2, 3, and 5). Of the four cases with hypotony due 
to hyperfiltration, in three cases the trabeculectomy had 
five scleral flap sutures, so no more were added postopera-
tively as IOP was normalized with corticosteroid treatment 
(two patients) or draining the choroidal detachment (one 
patient). In the remaining case, the trabeculectomy had three 
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scleral flap sutures and IOP was normalized by adding two 
complementary sutures to the scleral flap. In case 4, statisti-
cal hypotony persisted for 2 weeks until vitrectomy was 
performed. Preoperative OCT showed chorioretinal folds 
without epiretinal membranes or ILM thickening in any 
case. All of these cases had posterior vitreous detachment 
preoperatively.
Before surgery, median BCVA was 0.7 (range 0.26–2.3) 
logMAR, and postoperatively was 0.6 (range 0.3–0.7) 
logMAR at 4 months and 0.5 (range 0.2–1) logMAR at 
12 months. There was no statistically significant difference 
between preoperative and postoperative BCVA or between 
BCVA at 4 and 12 months. All five patients had preopera-
tive metamorphopsia, which was still present (albeit but less 
intense) at one year after surgery. Median IOP at 12 months 
after surgery was 12 (range 11–18) mmHg, without the need 
for hypotensive drops or anti-glaucoma surgery in any of 
these patients and stable visual fields. The stage of glaucoma 
persisted as moderate in all cases (based on the new ICD-9 
staging definitions). No postoperative complications were 
observed, and no cases presented hypotony at 24 hours or at 
follow-up 7 days later.
Hyperpigmentation lines were observed in the troughs of 
folds in the macular area in 3 cases at 30, 32, and 56 weeks 
after diagnosis of hypotony, corresponding to patients 
with the most prolonged clinical and statistical hypotony 
(24–28 weeks). Hyperpigmentation lines in the postoperative 
period progressed despite resolution of retinal folds, because 
choroidal folds persisted (Figure 1). This progression 
occurred in parallel with decreasing BCVA in two cases, 
while in the remaining patient BCVA remained stable.
Discussion
Ocular hypotony can lead to complications including 
HM, keratopathy, cataract, choroidal effusion, optic nerve 
edema, visual loss, and phthisis bulbi. However, many eyes 
with hypotony do not develop any of these complications.6 
Therefore, hypotony per se is not the causal agent but rather 
a predisposing factor. In our sample, all patients had myopia. 
This is a known risk factor for development of HM, as the 
thin sclera in these eyes offers no resistance to scleral collapse 
during hypotony. In addition, vitreoretinal characteristics in 
patients with high myopia may hinder determination of fun-
duscopic changes in HM. However, medical history together 
with IOP and OCT values  help to make the diagnosis. Besides 
this, there are other risk factors, such as topical application 
























































































































































































































































































































































































































































































































































































































































































































































The primary objective before treatment was to identify 
the etiology of HM in each case and then implement mea-
sures to increase the IOP as soon as possible in order to 
reverse scleral contraction. Various treatments have been 
described for the management of hyperfiltration due to 
aqueous humor leakage through the filtration bleb, including 
contact lenses, simulating bleb fibrosis (using concentrates 
of fibrinogen or blood, gentamicin, YAG laser therapy, 
cryotherapy, diathermy, trichloroacetic acid), supplementary 
sutures, bleb excision, and use of a scleral patch graft.2 Three 
cases had primary hyperfiltration; one patient (case 1 with 
IOP 6.5 mmHg) received topical corticosteroid and another 
(case 3) was treated with supplementary scleral sutures, with 
good results; and in the patient with primary hyperfiltra-
tion plus non-self-limiting choroidal detachment (case 2), 
drainage via the sclerotomy was performed, but IOP did 
not normalize until introduction of steroids. The patient 
with HM secondary to trauma (case 4) received subtenonian 
corticosteroid therapy in an attempt to reduce inflammation 
of the ciliary body and restore production of aqueous humor, 
without success. In our series, the patient with cyclodialysis 
(case 5) was unsuccessfully treated with subtenonian steroids 
to raise IOP, so cryocoagulation was then performed with 
application of intraocular SF6 gas, with good results.
Measures adopted to increase IOP should be chosen 
according to the etiology of the hypotony. However, the 
sample size in our series was too small to be able to draw 
conclusions about the success rate of the measures adopted 
to increase IOP in each disease.
Macular folds secondary to hypotony are sometimes 
irreversible despite normalization of IOP and may be sec-
ondary to ILM thickening. Duker et al were the first into 
propose vitreoretinal surgery to treat this structural change.9 
They described a case of HM with cataract extraction and 
PPV with posterior hyaloid peeling (but not ILM peeling) 
and perfluorocarbon liquid, which resulted in an increase 
of IOP to 50 mmHg over 10 minutes. The choroidal folds 
resolved and visual acuity improved, but stellate retinal folds 
persisted. However, we must take into account the concomi-
tant cataract extraction and the fact that these levels of IOP 
are not desirable in patients with glaucoma. We believe the 
reason for the persistent stellate retinal folds in that case was 
related to the absence of ILM peeling. In accordance with 
Benson et al11 and Mutoh et al12 who reported excellent visual 
Figure 1 (A) Preoperative hypotony maculopathy shown by posterior pole biomicroscopy (A1) and by optical coherence tomography (A2) in case 1. (B) Biomicroscopy 
(B1) and optical coherence tomography obtained one year after vitreoretinal surgery (B2) in case 1. Note the increase of hyperpigmentation (B1) despite resolution of the 
retinal folds, but not the choroidal folds (B2) in case 1.
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and functional results, along with others, our surgical tech-
nique aimed to eliminate the ILM around the posterior pole 
in order to achieve relaxation of the retinal surface, freeing 
it from traction and allowing reapplication of the folds by 
means of non-expandable gas tamponade using 20% SF6. 
This treatment is based on the hypothesis that persistent 
chorioretinal folds can remain irreversible, possibly due to 
ILM fibrocellular proliferation caused by incorrect retinal 
positioning, leading to irregular fixation of the retina and 
choroid.11,13,14 However, fibrocellular proliferation of the ILM 
was not revealed by preoperative OCT, possibly because it 
involved a single layer of cells that would be difficult to detect 
with biomicroscopy or OCT.14 After ILM peeling, the retinal 
folds disappeared in all cases. On the other hand, although 
the retinal structures are well preserved after ILM peeling, 
the vitreoretinal interface may be damaged, thus affecting the 
final prognosis.15–17 Studies comparing PPV with or without 
ILM peeling would be necessary to clarify the benefit of 
peeling in these patients.
Gass described how the retinal pigment epithelium 
became stacked and compressed in the troughs of the cho-
rioretinal folds, forming lines of hyperpigmentation that 
persisted despite chorioretinal flattening.4 In our series, 
three patients with prolonged hypotony (6–7 months) pre-
sented such lines of hyperpigmentation in the macula one 
year before treatment. The hyperpigmentation progressed 
despite postoperative retinal flattening, probably due to 
persistent folds at the choroidal level, detected by OCT 
(Figure 1). The exact time to appearance of these lines is 
difficult to calculate; in our series, it was between 7.5 and 
14 months after appearance of choroidal folds (unresolved 
with vitrectomy). However, at 12-month follow up, one 
of the cases with persistent choroidal folds had still not 
presented macroscopic hyperpigmentation lines. We do 
not rule out appearance of these lines during a longer 
follow-up period.
After treatment, both retinal and choroidal folds disap-
peared in the case with the shortest duration of hypotony 
6.5 mmHg (2 weeks), and it was this patient who presented 
best visual results. In the other cases with a longer dura-
tion of hypotony (4.5–7 months), choroidal folds persisted 
despite the vitrectomy, and it was these patients (with good 
glaucoma control) who presented the worst visual results. 
According to Gass, hyperpigmentation leads to a decrease 
in visual acuity because of impairment of photoreceptors 
outer segments, which generates residual changes in retinal 
pigment epithelium.4 In our series, two of the three cases 
with hyperpigmentation showed decreased BCVA in parallel 
with progression of hyperpigmentation lines. However, OCT 
failed to show defects in the photoreceptors due to their mask-
ing by the chorioretinal atrophy produced in high myopia 
(Figure 1).18 For these reasons, we wonder how authors such 
as Oyakhire et al18 or Delgado et al19 were able to achieve 
good functional and visual results without describing retinal 
pigment epithelium changes in the resolution of HM at 5 and 
7 years of evolution, respectively. We have in fact observed 
photoreceptor impairment in a patient not included in the 
present study: he had retinal folds after retinal detachment 
surgery, and postoperatively we observed that the hyperpig-
mentation coincided with the area of atrophy of the union of 
photoreceptors outer and inner segments, with progressive 
loss of visual acuity.
Thus, we believe that the main predictors of successful 
HM surgery are duration of preoperative hypotony and 
residual changes in the retinal pigment epithelium gener-
ated by hyperpigmentation which negatively affect the 
photoreceptors. For this reason, we believe that macular 
folds should be treated as soon as possible to improve the 
visual prognosis, identifying the cause and normalizing IOP. 
In cases where this approach is unsuccessful, vitreoretinal 
surgery should be considered, especially before hyper-
pigmentation lines appear. However, the appropriate time 
to perform such surgery should be evaluated in a greater 
number of patients.
In conclusion, macular changes secondary to hypotony 
may persist despite normalization of IOP. A good treatment 
option involves surgery to resolve the structural retinal 
changes with ILM peeling and subsequent non-expandable 
gas tamponade. However, BCVA may fail to improve in 
cases with long-standing macular folds due to irreversible 
changes at the retinal level. We therefore recommend treating 
HM as early as possible.
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